Autolus Limited, a London, UK-based clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, closed on a US$80m (£59m) Series C financing.
Backers included new investors Cormorant Asset Management, Nextech Invest and founding investor Syncona Ltd, Woodford Investment Management and Arix Bioscience.
The company intends to use the proceeds to establish clinical proof of concept for three novel haematological cancer programs:
– AUTO2 in multiple myeloma,
– AUTO3 in diffuse large B cell lymphoma and paediatric acute lymphoblastic leukaemia, and
– AUTO4 in T-cell lymphoma.
In addition, Autolus plans to advance its pre-clinical pipeline products for solid tumour indications, and will set up the infrastructure required for bringing a CAR-T cell therapy rapidly and successfully to market.
Led by Dr Christian Itin, Chairman and CEO, Autolus is a private, clinical-stage, biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products to combat cancer.
The company has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.